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Abstract
In this study, various 3′R,4′R-disubstituted-2′,2′-dimethydihydropyrano[2,3-f]chromone (DSP)
derivatives were discovered as potent chemosensitizers in the treatment of multidrug resistant
cancer cells. Twenty-four DSP analogs (5–28) were synthesized and evaluated against a multi-
drug resistant (MDR) cell line (KB-Vin) with and without vincristine (VCR). All DSP analogs
exhibited low intrinsic cytotoxicity. However, in combination treatment, most DSPs reversed
resistance to VCR and lowered the GI50 value of VCR by 12–349-fold. At a concentration of 1μg/
mL, three compounds, 11, 14 and 21, fully reversed resistance to VCR in KB-Vin cancer cells, a
twofold increase compared to verapamil, a first generation chemosensitizer. Detailed structure-
activity relationship (SAR) conclusions were established based on 3′ and 4′ substitutions.
Moreover, a preliminary mechanism study indicated that the chemosensitizing activity of DSP
analogs results from inhibition of P-glycoprotein (P-gp) over-expressed in MDR cancer cells.1
Introduction
Resistance of cancer cells to anticancer drugs remains one of the major obstacles in
achieving an effective treatment for cancer. Three primary mechanisms of anti-cancer drug
resistance have been identified: decreased uptake of water-soluble drugs; various changes in
cells that affect the capacity of cytotoxic drugs to kill cells; and the most commonly
encountered, increased energy-dependent efflux of hydrophobic cytotoxic drugs by one of a
family of energy-dependent transporters, such as P-gp (also known as MDR1).1 One
approach used in clinical research to reverse MDR is the development of chemosensitizers,
1Abbreviations: DSP, 3′R,4′R-di-substituted-2′,2′-dimethyldihydropyrano[2,3-f]chrmone; MDR, multi-drug resistance; VCR,
vincristine; P-gp, P-glycoprotein; PA, (±)-Praeruptorin A; DMDCK, (±)-3′-O-4′-O-bis(3,4-dimethoxycinnamoyl)-cis-khellactone; HB,
hydrogen bond.
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especially drugs that target P-gp and inhibit its activity. Verapamil and cyclosporine A
(Figure 1) are examples of first generation chemosensitizers that inhibit the activity of P-gp
and were evaluated clinically as adjuvants for chemotherapy. Both compounds are able to
increase the intracellular concentration of cytotoxic agents, such as VCR,
cyclophosphamide, dexamethasone, and doxorubicin, in MDR cells.2, 3 Moreover, both
verapamil and cyclosporine A are widely used medications, verapamil as a calcium channel
blocker to treat hypertension and cyclosporine A as an immunosuppressant to reduce the
activity of the patient's immune system in post-allogeneic organ transplant. However,
clinical studies showed that both compounds were generally toxic at the doses required to
attenuate P-gp function.4 Since then, several potent and selective next generation inhibitors
have been developed and investigated, but none of them have yet shown significant clinical
benefit. Inhibition of P-gp by chemosensitizers may also be problematic because drug
distribution and elimination can be affected by these agents. 4, 5 However, it is still possible
that the ideal chemotype for a chemosensitizer has yet to be identified and developed.
It has been reported that the naturally existing pyranocoumarin (±)-praeruptorin A (PA) and
its khellactone analogs with 3′,4′-modifications (Figure 2) can reverse P-gp-mediated MDR.
6, 7 (±)-3′-O-4′-O-bis(3,4-Dimethoxycinnamoyl)-cis-khellactone (DMDCK, 3) showed the
highest potency among these analogs. At a concentration of 4 μM, 3 was able to increase the
activity of the chemotherapy drug vinblastine over 110-fold.7 However, even at such a high
concentration, 3 was unable to completely reverse vinblastine resistance in the liver cancer
cell system used. 7 In addition, it was also reported that the side chains at the 3′ and 4′
positions of the khellactone system play an important role in maintaining high activity.
Unfortunately, only a few khellactone analogs with 3′,4′ modifications have been reported to
show potent chemosensitizing activity, so detailed SAR information is unavailable.
Therefore, continuing research to develop novel active analogs is merited, and forms the
basis for the work on the DSP series reported herein.
Design
Even before the structure of P-gp protein was resolved,8 a general pharmacophore model for
P-gp binding and inhibition was proposed based on verapamil.9 The pharmacophore consists
of a butterfly-shaped molecule with two hydrophobic motifs (aromatic ring system)
connected with a linker that contains hydrogen bond (HB) acceptors and/or donors.
DMDCK (3) was subsequently shown to fit the pharmacophore model and could be readily
docked into verapamil's hypothetical binding site on the protein subunit of P-gp.7, 9
DSPs (Figure 2) share certain structural similarities to DMDCK (3), which prompted us to
design and synthesize a series of 3′,4′-disubstituted-pyranochromone derivatives as new
chemosensitizing agents. It is likely that the pyranochromone moiety has similar HB
properties to those of khellactone in DMDCK. Incorporation of two side chains at the 3′ and
4′ positions with substitutions containing aromatic moieties could mimic the hydrophobic
moieties in verapamil and DMDCK (3). Based on this rationale, a series of 3′,4′-
disubstituted-pyranochromone derivatives with varied 3′ and 4′ side chains were designed,
synthesized, and screened against the MDR human esophageal cancer cell line (KB-Vin)
with or without combination of the anticancer drug VCR. This approach allowed us to
evaluate the intrinsic cytotoxicity of DSP analogs, as well as their ability to reverse MDR.
Chemistry
Compound 4, 3′R,4′R-2′,2′-dimethyl-dihydropyranochromone, is the core structure of all
target compounds and a key intermediate in all synthetic pathways. The synthesis of 4 has
been reported previously.10,11 Side chains with varied chain lengths and aromatic or non-
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aromatic functional groups at the chain terminus were introduced at the 3′ and 4′ positions of
the core scaffold (Scheme 1).
Compound 4 stirred with substituted benzoyl chloride or cyclohexyl carbonyl chloride in the
presence of DMAP at room temperature to afford 5–16 and 23. Reaction of phenylacetyl
chlorides or 3-phenylpropanoyl chloride with 4 gave 17–19, while reaction of 4 with trans-
cinnamoyl chlorides afforded 20–21.
3′,4′-Dibenzyloxy substituted DSP (22) was generated by reacting 4 with benzyl bromide in
the presence of NaH in DMF under N2 atmosphere (Scheme 1). 12
The synthesis of carbamates 24–28 was accomplished by treatment of 4 with N,N-
dialkylcarbamylchloride or pyrrolidine and piperidine carbonyl chloride, respectively, in
anhydrous THF in the presence of NaH (Scheme 1). 13
Results and Discussion
Chemosensitization Activity In Vitro
VCR is a potent mitotic inhibitor, and is widely used in combination chemotherapy of acute
leukemias and some solid tumors. The GI50 value of VCR against the KB (drug-sensitive)
cell line was 0.009 μg/mL (Table 1). Against the KB-Vin cell line, a multi-drug resistant
cancer cell line, the cytotoxic effect of VCR decreases dramatically, over 270-fold, and its
GI50 value is 2.44 μg/mL (Table 1). In order to determine the ability of DSPs to reverse
MDR in KB-Vin cells, the cytotoxic effect of VCR was evaluated with or without the
addition of each newly synthesized DSP analog.
In order to exclude the possibility that cytotoxicity of the combination treatment with VCR
and DSP might result from the cytotoxic effect of DSPs, all newly synthesized DSPs were
also screened individually against KB-Vin cells, and the results are shown in Table 1. In
general, all DSP analogs exhibited low intrinsic cytotoxic activity, similar to that of the
prototype first generation P-gp inhibitor verapamil.
The chemosensitizing activity of DSPs was then evaluated by measuring the cytotoxic effect
of VCR in the presence of DSP analogs at 1 μg/mL, using verapamil as the positive control.
As seen from the data in Table 1, most of the DSP analogs lowered the GI50 value of VCR,
and thus, reversed VCR resistance in the range of 12–349-fold. In comparison, verapamil
increased VCR sensitivity by 141-fold.
Compounds 5–16 are pyranochromones with benzoyloxy groups at the 3′ and 4′ positions.
Different functional groups were selectively introduced on the o-, m- or p-position of the
benzoyl rings. As shown in Table 1, except for 10, non-substituted, o-, and m-substituted
benzoyloxy-DSPs (5–9) exhibited lower chemosensitizing activity than corresponding p-
substituted compounds. Compounds 5, 6, and 8 failed to decrease the GI50 of VCR below
0.2 μg/mL, while o- and m-methoxy-substituted benzoyloxy-DSPs (7 and 9) exhibited only
moderate chemosensitizing activity by increasing the potency of VCR around 28-fold.
Compound 10, with an m-CN substituent, exhibited better chemosensitizing activity (160-
fold).
DSP analogs with p-substituted benzoyloxy rings (11–16) showed substituent-dependent
activity. Compounds 11 and 14 with methyl and methoxy substituents, respectively, showed
the most promising chemosensitizing activity. GI50 values of the combinations of 11 and 14
with VCR were 0.007 and 0.0095 μg/mL, respectively, corresponding to 349- and 257-fold
increased potency relative to VCR alone. The improved potency was greater than that with
verapamil. Interestingly, 12, with an ethyl group, had a substantially lower effect (20.3-fold
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VCR increase), and 13, substituted with a trifluoromethyl group, improved VCR activity by
only 16.3-fold. Compounds 15 and 16, with electron-withdrawing groups at the p-position,
showed enhancements of approximately 200-fold, which was better than that of verapamil.
These results suggested that p-substituents are generally preferred over o- or m-substituents
for chemosensitizing activity. Substituents with extended conjugation, e.g., CN or NO2
groups, and smaller less sterically hindered groups may benefit the efficacy of 3′,4′-
disubstituted DSPs as new potent chemosensitizers.
Compounds 17–21 were designed, synthesized, and evaluated in order to understand the
effects of adding a linker between the ester carbonyl group and the aromatic substituents in
the side chains. Introducing a saturated linker slightly increased the chemosensitizing ability,
with improved GI50 values of the VCR-DSP combination from over 0.2 μg/mL for 5
(−O2CC6H5), 0.03 μg/mL for 17 (−O2CCH2C6H5), and 0.023 μg/mL for 19
(−O2CCH2CH2C6H5). Unexpectedly, replacing the phenyl group of 17 with a p-
methoxyphenyl in 18 resulted in a 2.4-fold reduction in chemosensitizing efficacy, and 7.5
times reduction compared with 14, which also contains a p-methoxyphenyl group, but linked
directly to the ester carbonyl moiety. Compounds 20 and 21 have a conjugated double bond
between the ester carbonyl group and the phenyl ring. Interestingly, combination of either
compound with VCR led to significantly enhanced activity. Compound 20, with an
unsaturated vinyl group, showed twofold increased efficacy compared to 19, with a
saturated ethylene group. Compound 21, with p-methoxycinnamoyloxy 3′,4′ side chains,
was able to fully restore the cytotoxcitiy of VCR. The GI50 value of the VCR-21
combination was 0.0085 μg/mL, which was comparable to the values with 11 and 14, Thus,
cinnamic and p-methoxycinnamic esters linked to the core dihydropyranochromone
structure favored MDR reversal activity.
In order to investigate the impact of the carbonyl group in the active analogs, 22 was
synthesized. In this compound, the carbonyl moieties in the 3′ and 4′ side chains have been
replaced with a methylene group. With an ether rather than ester side chain, 22 will likely be
chemically and metabolically more stable than its analog 5. Interestingly, 22 showed better
capability to reverse MDR than 5. This finding shows that the carbonyl group may not be
essential for activity. Further SAR studies are needed to confirm this hypothesis.
To further investigate the importance of the 3′,4′-side chains, compounds 23–28, with
various 3′,4′-carbamate groups, were designed and synthesized. Most of these compounds,
which do not have an aromatic substituent in the side chains, showed either no or marginal
chemosensitizing activity. The exception was 25 (N,N-diethylcarbamoyloxy), which showed
ten times better efficacy than its counterparts 24 (N,N-dimethylcarbamoyloxy) and 26 (N,N-
dibutylarbamoyloxy). 25 also presented 5-fold more potency than its cyclic analogs 27 and
28, suggesting that the orientation of the N-alkyl substitutions at 3′ and 4′ positions affects
the interactions of the drug molecules and the binding pocket in the target protein, for
example, the different orientation between chain alkyl groups (25) and cyclic groups (27,
28), which, in turn, affects the activity.
In summary, three compounds, 11, 14 and 21, were found to be the most potent
chemosensitizers of VCR among 24 newly synthesized compounds. At a non-toxic
concentration, they are able to fully restore the cytotoxicity of VCR against KB-Vin, so that
the MDR cell line was as sensitive as the parent KB cell line. They were also over two times
better than the positive control verapamil (Table 1). While most of the active compounds
contain 3′,4′-ester side chains ending in an aromatic ring, 25, which contains two carbamate
side chains and no aromatic system, also exhibited considerable potency. The dicarbamate
25 should also exhibit increased polarity and different physicochemical properties, which
may benefit further development of new analogs with interesting biological activity.
Zhou et al. Page 4













The SAR study on 3′,4′ side chains suggested the following conclusions. 1. A terminal
aromatic ring is important but not necessary to maintain high chemosensitizing capability. 2.
Substituents on the aromatic rings can significant impact the activity. Moieties that have
increased electron density, extended conjugation systems, or HB effects can benefit efficacy.
3. The characteristic of the linker between the core structure and the aromatic ring system
can also affect the chemosensitizing potential. Extending the conjugation system by adding
double bond(s) benefits the activity.
Previous modification studies of PA and DCK (1) revealed that aromatic rings in the 3′ and
4′ side chains of the khellactone benefit the chemosensitizing activity, and in addition,
methoxy groups substituted on cinnamoyl side chains could impact the activity.7 Those
results are mostly, but not fully, consistent with those reported here for pyranochromone-
based DSP active analogs. For example, we found that 25, without an aromatic ring in the 3′,
4′-side chains displayed good chemosensitizing ability, and thus, an aromatic ring is not
essential for activity. In addition, our studies showed both positive (14 vs 5, 21 vs 20) and
negative (18 vs 17) effects for the addition of p-methoxy group on a phenyl ring. Fong et al.
also reported that p-methoxycinnamoyl-khellactone (MMDCK, 2) exhibited decreased
potency compared with DCK (1).7
Due to the different cell lines and MDR substrates, it is difficult to directly compare the
activities between the prior khellactone compounds and the DSP analogs reported here.
However, in both HepG2/Dox and KB-V1 cell lines, the best reported khellactone
compound, DMDCK (3) at 4 μM, could not completely restore the cytotoxicity of
vinblastine, an alkaloid analog of VCR. In contrast, DSP analogs 11, 14 and 21 completely
restored the cytotoxic effect of VCR suggesting they are more efficacious and more potent
than DMDCK (3).
Effect on Cellular P-gp Activity
The acquired VCR-resistance in the KB-Vin cell line is due to enhanced drug efflux via P-
gp over-expression.14 Our research results demonstrate that addition of DSPs could restore
VCR's cytotoxity againt KB-Vin, suggesting that DSP analogs might function like verapamil
as P-gp inhibitors. To test this hypothesis, the effect of DSP analogs on efflux of the P-gp
substrate calcein-AM was investigated using the established and widely used assay for
cellular P-gp function.15 Inhibition of P-gp leads to the accumulation of calcein-AM in the
cytoplasm and concomitant degradation by esterase action to give a fluorescent derivative
that can be conveniently monitored as a quantitative measure of P-gp inhibition. Four DSP
analogs (8, 13–15) were selected and their ability to facilitate calcein-AM influx was
examined and compared to that of verapamil as the positive inhibitor control. The results are
shown in Figure 3. Compounds 15 and 14, which showed improved activity versus
verapamil in the chemosensitization assay (Table 1), also exerted more potent inhibition of
cellular P-gp based on the functional assay results. Compound 13, which showed weaker
chemosensitizing activity versus verapamil (16- and 142- fold respectively, Table 1), was
correspondingly less active as a P-gp inhibitor. Compound 8 exerted no effect on calcein-
AM efflux, which is consistent with its lack of chemosensitization activity. These results
demonstrate that the rank-order of chemosensitizing efficacy of DSP analogs is consistent
with their relative inhibitory activity toward cellular P-gp. Thus, DSP analogs most likely
act as pump inhibitors in the KB-MDR cell system.
Conclusions
Novel DSP analogs with significant chemosensitizing activity in a MDR human cancer cell
line were discovered. An SAR study on the 3′ and 4′ side chains of pyranochromone ring
was conducted with the following conclusions. p-Substitution on the aromatic ring in the
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side chain is better than o- and m-substitution. Small substitutions that can increase electron
density or provide hydrogen-bonding capacity at the putative interaction domain on P-gp
benefit the activity. The length and identity of the linker is also important and a conjugated
double-bond is favorable. Compared with verapamil, a prototype first generation
chemosensitizer, nine DSPs exhibited improved or comparable chemosensitizing potential.
Compounds 11, 14, and 21 fully overcame VCR resistance in KB-Vin cancer cells at a
concentration of 1 μg/mL (1.64–1.90 μM range). Compared to recent work on khellactone-
based chemosensitizers, our study provides a more comprehensive SAR and discovered DSP
analogs with more promising potency at lower concentration. Preliminary work indicates
that the chemosensitizing activity of DSP analogs results from P-gp inhibition. Detailed
mechanistic studies are currently ongoing.
Experimental Section
Chemistry
Melting points were measured with a Fisher Johns melting apparatus without correction. The
proton nuclear magnetic resonance (1H NMR) spectra were measured on a 300 MHz Varian
Gemini 2000 spectrometer and a Varian Inova 400 MHz spectrometer using TMS as internal
standard. The solvent used was CDCl3 unless indicated. Microwave reactions were
performed with a Biotage initiator EXP US. Mass spectra were measured on a Shimazu
LCMS-2010 (ESI-MS). Optical rotation was measured with a Jasco Dip-2000 digital
polarimeter at 20 °C at the sodium D line. Thin-layer chromatography (TLC) was performed
on PLC silica gel 60 F254 plate (20 × 20, Merck). Biotage Flash and Isco companion
systems were used for medium-pressure column chromatography. Silica 40 μM columns
from Grace Inc. were used for column chromatography. All final compounds are >95% pure
on the basis of HPLC.
Synthesis of compounds 5-21 and 23—A mixture of compound 4 (1 equiv),
substituted benzoyl cholorde, cyclohenxal chloride, phenylacetyl chlorides, 3-
phenylpropanoyl chloride, or trans-cinnamoyl chlorides (3 equiv), and DMAP (4 equiv)
were stirred in CH2Cl2 for 1-2 h at rt, monitored by TLC. At completion, the mixture was
diluted with CH2Cl2 and washed with water and brine. The solvent was then removed under
reduced pressure and the residue was purified by PTLC with hexane:EtOAc = 3:2 to afford
the appropriate compounds (5–21 and 23).
3′R,4′R-Di-benzoyloxy-2′,2′-dimethyl-2-ethyldihydropyrano[2,3-f]chromone (5)
—85% yield (starting from 30 mg of 4); white solid; mp 63-65 °C; 1NMR δ 8.15 (1H, d, J =
8.8 Hz, H-5), 8.10-8.13 (1H, m, benzoyl-3′,4′), 7.87-7.90, 7.46-7.61, 7.32-7.46 (each 3H, m,
bezoyl-3′,4′), 7.01 (1H, d, J = 4.8 Hz, H-4′), 6.99 (1H, d, J = 8.8 Hz, H-6), 6.08 (1H, s, H-3),
5.66 (1H, d, J = 4.8 Hz, H-3′), 2.34 (2H, q, J = 8.0 Hz, CH2CH3-2), 1.69, 1.54 (each 3H, s,
CH3-2′), 1.02 (3H, t, J = 8.0 Hz, CH2CH3-2); [α]D −82.9 ° (c = 0.0035, CHCl3); HRMS for
(M+ + H): calcd m/z 499.1757, found: 499.1735.
3′R,4′R-Di-(2-trifluoromethylbenzoyloxy)-2′,2′-dimethyl-2-
ethyldihydropyrano[2,3-f] chromone (6)—88% yield (starting from 30 mg of 4);
white solid; mp = 104-106 °C; 1NMR δ 7.95 (1H, d, J = 8.8 Hz, H-5), 7.50-7.80 (8H, m,
benzoyl-3′,4′), 6.65 (1H, d, J = 8.8 Hz, H-6), 6.30 (1H, s, H-3), 5.85 (1H, d, J = 4.8 Hz,
H-4′), 5.50 (1H, d, J = 4.8 Hz, H-3′), 2.34 (2H, q, J = 8.0 Hz, CH2CH3-2), 1.69, 1.54 (each
3H, s, CH3-2′), 1.02 (3H, t, J = 8.0 Hz, CH2CH3-2). [α]D −34.7 ° (c = 0.0019, CHCl3);
HRMS for (M+ + H): calcd m/z 635.1504, found: 635.1493.
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f]chromone (7)—80% yield (starting from 30 mg of 4); white solid; mp = 104-106
°C; 1NMR δ 8.18, 7.81, 7.63, 7.07 (each 1H, d, J = 7.6 Hz, methoxybenzoyl-3′,4′), 8.11 (1H,
d, J = 8.8 Hz, H-5), 7.44, 7,42, 6.93, 6.90 (each 1H, t, J = 7.6 Hz, methoxybenzoyl-3′,4′),
7.00 (1H, d, J = 4.8 Hz, H-4′), 6.94 (1H, d, J = 9.0, H-5), 6.09 (1H, s, H-3), 5.62 (1H, d, J =
4.8 Hz, H-3′), 3.77, 3.70 (each 3H, s, methoxybenzoyl-OCH3-3′,4′), 2.48 (2H, q, J = 7.5 Hz,
CH2CH3-2), 1.63, 1.56 (each 3H, s, CH3-2′), 1.14 (3H, t, J = 7.5 Hz, CH2CH3-2); [α]D
−40.0 ° (c = 0.0007, CHCl3); HRMS for (M+ + H): calcd m/z 559.1963, found: 559.1937.
3′R,4′R-Di-(3-trifluoromethylbenzoyloxy)-2′,2′-dimethyl-2-
ethyldihydropyrano[2,3-f] chromone (8)—80% yield (starting from 100 mg of 4);
white solid; mp = 124-126 °C; 1NMR δ 8.15 (1H, d, J = 8.8 Hz, H-5), 8.02-8.07 (4H, m,
benzoyl-3′,4′), 7.77-7.82 (2H, m, benzoyl-3′,4′), 7.49-7.55 (2H, m, benzoyl-3′,4′), 6.99 (1H,
d, J = 4.2 Hz, H-4′), 6.98 (1H, d, J = 8.8 Hz, H-6), 6.06 (1H, s, H-3), 5.67 (1H, d, J = 4.2
Hz, H-3′), 2.33 (2H, q, J = 7.6 Hz, CH2CH3-2), 1.68, 1.54 (each 3H, s, CH3-2′), 1.02 (3H, t,
J = 7.6 Hz, CH2CH3-2); [α]D −74.6 ° (c = 0.0013, CHCl3); HRMS for (M+ + H): calcd m/z
635.1504, found: 635.1514.
3′R,4′R-Di-(3-methoxybenzoyloxy)-2′,2′-dimethyl-2-ethyldihydropyrano[2,3-
f]chromone (9)—80% yield (starting from 30 mg of 4); white solid; mp = 90-92 °C; MS-
ESI + (m/z, %) 559 (M+ + 1, 100); 1NMR δ 8.09 (1H, d, J = 8.4 Hz, H-5), 7.71, 7.68 (each
1H, d, J = 7.6 Hz, benzoyl-3′,4′), 7.61 (2H, s, benzoyl-3′,4′), 7.38 (2H, t, J = 8.4, 7.6 Hz,
benzoyl-3′,4′), 7.15 (2H, J = 8.4 Hz, benzoyl-3′,4′), 6.93 (1H, d, J = 8.4 Hz, H-6), 6.17 (1H,
s, H-3), 5.53 (1H, d, J = 4.8 Hz, H-4′), 5.41 (1H, d, J = 4.8 Hz, H-3′), 3.87, 3.85 (each 3H, s,
3-methoxybenzoyl-OCH3-3′,4′), 2.65 (2H, q, J = 7.6 Hz, CH2CH3-2), 1.61, 1.49 (each 3H, s,
CH3-2′), 1.30 (3H, t, J = 7.6 Hz, CH2CH3-2); [α]D −116.3 ° (c = 0.0008, CHCl3); HRMS for
(M+ + H): calcd m/z 599.1968, found: 599.1986.
3′R,4′R-Di-(3-cyanolbenzoyloxy)-2′,2′-dimethyl-2-ethyl-dihydropyrano[2,3-
f]chromone (10)—65% yield (starting from 100 mg of 4); white solid; mp = 253-254
°C; 1NMR δ 8.19 (1H, d, J = 9.0 Hz, H-5), 8.11 (4H, m, benzoyl-3′,4′), 7.86, 7.58 (each 2H,
m, benzoyl-3′,4′), 7.02 (1H, d, J = 9.0 Hz, H-6), 7.00 (1H, d, J = 5.4 Hz, H-4′), 6.16 (1H, s,
H-3), 5.66 (1H, d, J = 5.4 Hz, H-3′), 2.36 (2H, q, J = 7.8 Hz, CH2CH3-2), 1.69, 1.57 (each
3H, s, CH3-2′), 1.03 (3H, t, J = 7.8 Hz, CH2CH3-2); [α]D −125.0 ° (c = 0.0004, CHCl3);
HRMS for (M+ + H): calcd m/z 549.1662, found: 549.1666.
3′R,4′R-Di-(4-methylbenzoyloxy)-2′,2′-dimethyl-2-ethyldihydropyrano[2,3-
f]chromone (11)—80% yield (starting from 25 mg of 4); white solid; mp = 144-145
°C; 1NMR δ 8.13 (1H, d, J = 9.0 Hz, H-5), 7.78, 7.78 (each 2H, d, J = 8.1 Hz,
COOC(CHCH)2CCH3-3′,4′), 7.17, 7.17 (each 2H, d, J = 8.1 Hz, COOC(CHCH)2CCH3-3′,
4′), 6.97 (1H, d, J = 9.0 Hz, H-6), 6.96 (1H, d, J = 4.8 Hz, H-4′), 6.07 (1H, s, H-3), 5.62 (1H,
d, J = 4.8 Hz, H-3′), 2.39, 2.38 (each 3H, s, methylbenzoyl-CH3-3′,4′), 2.34 (2H, q, J = 7.5
Hz, CH2CH3-2), 1.67, 1.53 (each 3H, s, CH3-2′), 1.02 (3H, t, J = 7.5 Hz, CH2CH3-2); [α]D
−81.3 ° (c = 0.0015, CHCl3); HRMS for (M+ + H): calcd m/z 527.2070, found: 527.2063.
3′R,4′R-Di-(4-ethylbenzoyloxy)-2′,2′-dimethyl-2-ethyldihydropyrano[2,3-
f]chromone (12)—70% yield (starting from 65 mg of 4); white powder; mp = 109-102
°C; 1NMR δ 8.13 (1H, d, J = 9.0 Hz, H-5), 7.80, 7.80 (each 2H, d, J = 7.2 Hz,
COOC(CHCH)2CCH2CH3-3′,4′), 7.20, 7.17 (2H, d, J = 7.2 Hz,
COOC(CHCH)2CCH2CH3-3′,4′), 6.98 (1H, d, J = 9.0 Hz, H-6), 6.97 (1H, d, J = 4.8 Hz,
H-4′), 6.07 (1H, s, H-3), 5.63 (1H, d, J = 4.8 Hz, H-3′), 2.69, 2.68 (each 2H, q, J = 7.5 Hz,
ethylbenzoyl-CH2CH3-3′,4′), 2.32 (2H, q, J = 7.5 Hz, CH2CH3-2), 1.68, 1.53 (each 3H, s,
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H-2′), 1.24(3H, t, J = 7.5 Hz, CH2CH3-2), 1.23, 1.03 (each 3H, t, J = 7.2 Hz ethylbenzoyl-
CH2CH3-3′,4′); [α]D −93.6 ° (c = 0.01, CHCl3); HRMS for (M+ + H): calcd m/z 555.2383,
found: 555.2366.
3′R,4′R-Di-(4-trifluoromethylbenzoyloxy)-2′,2′-dimethyl-2-ethyl-
dihydropyrano[2,3-f] chromone (13)—60% yield (starting from 25 mg of 4); white
powder; mp = 114-115 °C; 1NMR δ 8.22 (2H, d, J = 8.1 Hz, trifluoromethylbenzoyl-H),
8.16 (1H, d, J = 8.7 Hz, H-5), 8.99 (2H, d, J = 8.4 Hz, trifluoromethylbenzoyl-H), 7.74, (2H,
d, J = 8.1 Hz, trifluoromethylbenzoyl-C(CHCH)2CCF3-3′,4′), 7.65 (2H, d, J = 8.4 Hz,
trifuoromethylbenzoyl- C(CHCH)2CCF3-3′,4′), 7.00 (1H, d, J = 8.7 Hz, H-6), 7.00 (1H, d, J
= 4.8 Hz, H-4′), 6.12 (1H, s, H-3), 5.67 (1H, d, J = 4.8 Hz, H-3′), 2.33 (2H, q, J = 7.8 Hz,
CH2CH3-2), 1.68, 1.56 (each 3H, s, CH3-2′), 1.02 (3H, t, J = 7.8 Hz, CH2CH3-2); [α]D
−74.0 ° (c = 0.0025, CHCl3); HRMS for (M+ + H): calcd m/z 635.1504, found: 635.1488.
3′R,4′R-Di-(4-methoxybenzoyloxy)-2′,2′-dimethyl-2-ethyl-dihydropyrano[2,3-
f]chromone (14)—80% yield (starting from 100 mg of 4); yellow oil; 1NMR δ 8.13 (1H,
d, J = 8.7 Hz, H-5), 7.85, 7.85 (each 2H, d, J = 8.7 Hz, COOC(CHCH)2COCH3-3′,4′), 6.97
(1H, d, J = 8.7 Hz, H-6), 6.95 (1H, d, J = 4.8 Hz, H-4′), 6.85, 6.82 (each 2H, d, J = 8.7 Hz,
COOC(CHCH)2COCH3-3′,4′), 6.06 (1H, s, H-3), 5.61 (1H, d, J = 4.8 Hz, H-3′), 3.85, 3.84
(each 3H, s, methoxybenzoyl-OCH3-3′,4′), 2.33 (2H, q, J = 7.2 Hz, CH2CH3-2), 1.66, 1.53
(each 3H, s, CH3-2′), 1.03 (3H, t, J = 7.2 Hz, CH2CH3-2); [α]D −105.0 ° (c = 0.0012,
CHCl3); HRMS for (M+ + H): calcd m/z 559.1968, found: 559.1954.
3′R,4′R-Di-(4-cyanobenzoyloxy)-2′,2′-dimethyl-2-ethyl-dihydropyrano[2,3-
f]chromone (15)—80% yield (starting from 100 mg of 4); white powder; mp = 253-254
°C; 1NMR δ 8.17 (1H, d, J = 8.7 Hz, H-5), 7.98, 7.97 (each 2H, d, J = 8.7 Hz, benzoyl-
COC(CHCH)2CCN-3′,4′), 7.71, 7.68 (each 2H, d, J = 8.7 Hz, benzoyl-
COC(CHCH)2CCN-3′,4′), 6.99 (1H, d, J = 8.7 Hz, H-6), 6.98 (1H, d, J = 5.1 Hz, H-4′), 6.08
(1H, s, H-3), 5.66 (1H, d, J = 5.1 Hz, H-3′), 2.34 (2H, t, J = 7.8 Hz, CH2CH3-2), 1.67, 1.56
(each 3H, s, CH3-2′), 1.01 (3H, t, J = 7.8 Hz, CH2CH3-2); [α]D −104.8 ° (c = 0.0014,
CHCl3); HRMS for (M+ + H): calcd m/z 549.1662, found: 549.1648.
3′R,4′R-Di-(4-nitrolbenzoyloxy)-2′,2′-dimethyl-2-ethyl-dihydropyrano[2,3-
f]chromone (16)—50% yield (starting from 50 mg of 4); white solid; mp = 109-110
°C; 1NMR δ 8.23, 8.22 (each 2H, d, J = 9.0 Hz, COOC(CHCH)2CNO2-3′,4′), 8.14 (1H, d, J
= 8.4 Hz, H-5), 8.06, 8.04 (each 2H, d, J = 9.0 Hz, COOC(CHCH)2CNO2-3′,4′), 6.99 (1H,
d, J = 8.4 Hz, H-6), 6.98 (1H, d, J = 4.8 Hz, H-4′), , 6.06 (1H, s, H-3), 5.67 (1H, d, J = 4.8
Hz, H-3′), 2.33 (2H, q, J = 7.2 Hz, CH2CH3-2), 1.68, 1.57 (each 3H, s, CH3-2′), 1.00 (3H, t,
J = 7.2 Hz, CH2CH3-2); [α]D −74.7 ° (c = 0.0015, CHCl3); HRMS for (M+ + H): calcd m/z
589.1458, found: 589.1437.
3′R,4′R-Di-(2-phenylacetoxy)-2′,2′-dimethyl-2-ethyl-dihydropyrano[2,3-
f]chromone (17)—53% yield (starting from 30 mg of 4); solid powder; mp = 75-77
°C; 1NMR δ 8.07 (1H, d, J = 8.8 Hz, H-5), 7.30 (10H, m, phenyl-3′,4′), 6.85 (1H, d, J = 8.8
Hz, H-6), 6.58 (1H, d, J = 4.8 Hz, H-4′), 6.05 (1H, s, H-3), 5.20 (1H, d, J = 4.8Hz, H-3′),
3.53, 3.46 (each 2H, d, J = 15.9 Hz, acetoxy-COOCH2-3′,4′), 2.25 (2H, q, J = 7.6 Hz,
CH2CH3-2), 1.32, 1.25 (each 3H, s, CH3-2′), 1.12 (3H, t, J = 7.6 Hz, CH2CH3-2); [α]D
−60.0 ° (c = 0.0015, CHCl3); HRMS for (M+ + H): calcd m/z 527.2070, found: 527.2060.
3′R,4′R-Di-[2-(4-methoxyphenylacetoxy)]-2′,2′-dimethyl-2-ethyl-
dihydropyrano[2,3-f] chromone (18)—50% yield (starting from 25 mg of 4); yellow
oil; 1NMR δ 8.07 (1H, d, J = 9.0 Hz, H-5), 7.20, 7.17 (each 2H, d, J = 8.7 Hz, phenyl-
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C(CHCH)2COCH3-3′,4′), 6.87, 6.85 (each, 2H, d, J = 8.7 Hz, phenyl-C(CHCH)2COCH3-3′,
4′), 6.78 (1H, d J = 9.0 Hz, H-6), 6.44 (1H, d, J = 4.8 Hz, H-4′), 6.10 (1H, s, H-3), 4.03 (1H,
d, J = 4.8 Hz, H-3′), 2.25 (2H, q, J = 7.5 Hz, CH2CH3-2), 1.49, 1.34 (each 3H, s, CH3-2′),
1.13 (3H, t, J = 7.5 Hz, CH2CH3-2); [α]D −47.7 ° (c = 0.0013, CHCl3); HRMS for (M+ +
H): calcd m/z 587.2281, found: 587.2266.
3′R,4′R-Di-(3-phenylpropanoyloxy)-2′,2′-dimethyl-2-ethyl -dihydropyrano[2,3-
f]chromone (19)—70% yield (starting from 25 mg of 4); clear oil; 1NMR δ 8.09 (1H, d, J
= 9.0 Hz, H-5), 7.22 (10H, m, phenyl-C(CHCH)2CH-3′,4′), 6.88 (1H, d, J = 9.0 Hz, H-6),
6.59 (1H, d, J = 4.8 Hz, H-4′), 6.09 (1H, s, H-3), 5.26 (1H, d, J = 4.8 Hz, H-3′), 2.95, 2.95
(4H, t, J = 7.6 Hz, propanoyl-CH2CH2-3′.4′), 2.67, 2.58(each 2H, t, J = 7.6 Hz, propanoyl-
CH2CH2-3′,4′), 2.46 (2H, q, J = 7.5 Hz, CH2CH3-2), 1.43, 1.33 (each 3H, s, CH3-2′), 1.67
(3H, t, J = 7.5 Hz, CH2CH3-2); [α]D −74.8 ° (c = 0.0023, CHCl3); HRMS for (M+ + H):
calcd m/z 555.2393, found: 555.2378.
3′R,4′R-Di-(E)- phenylacryloyloxy-2′,2′-dimethyl-2-ethyl-
dihydropyrano[2,3f]chromone (20)—65% yield (starting from 50 mg of 4); white
solid; mp = 104-106 °C; 1NMR δ 8.05 (1H, d, J = 9.0 Hz, H-5), 7.63, 7.63 (each 1H, d, J =
15.9 Hz COOCHCH-3′,4′), 7.36-1.40 (5H, m, phenyl-3′,4′), 1.23-1.29 (5H, m, phenyl-3′,4′),
6.88 (1H, d, J = 9.0 Hz, H-6), 6.75 (1H, d, J = 4.8 Hz, H-4′), 6.38 (2H, d, J = 15.9 Hz,
COOCHCH-3′.4′), 6.02 (1H, s, H-3), 5.42 (1H, d, J = 4.8 Hz, H-3′), 2.42 (2H, q, J = 6.9 Hz,
CH2CH3-2), 1.52, 1.43 (each 3H, s, CH3-2′), 1.17 (3H, t, J = 6.9 Hz, CH2CH3-2); [α]D
−75.3 ° (c = 0.0017, CHCl3); HRMS for (M+ + H): calcd m/z 551.2070, found: 551.2074.
3′R,4′R-Di-(E)-4-methoxyphenylacryloyloxy-2′,2′-dimethyl-2-ethyl-
dihydropyrano[2,3f] chromone (21)—50% yield (starting from 25 mg of 4); white
powder; mp = 94-96 °C; 1NMR δ 8.10 (1H, d, J = 9.0 Hz, H-5), 7.66, 7.65 (each 1H, d, J =
15.3 Hz, (E)-acryloxy-OCOCHCH-3′,4′), 7.40 (4H, dd, J = 8.7, 3.0 Hz, 4-methoxyphenyl-
C(CHCH)2COCH3-3′,4′), 6.93 (1H, d, J = 9.0 Hz, H-6), 6.85 (4H, dd, J = 8.7, 3.0 Hz, 4-
methoxyphenyl-C(CHCH)2COCH3-3′,4′), 6.80 (1H, d, J = 4.8 Hz, H-4′), 6.33, 6.32 (each
1H, d, J = 15.3 Hz, (E)-acryloxy-OCOCHCH-3′,4′), 6.10 (1H, s, H-3), 5.47 (1H, d, J = 4.8
Hz, H-3′), 6.65 (6H, s, OCH3-3′,4′), 2.47 (2H, q, J = 7.5 Hz, CH2CH3-2), 1.58, 1.49 (each
3H, s, CH3-2′), 1.59 (3H, t, J = 7.5 Hz, CH2CH3-2); [α]D −70.0 ° (c = 0.0043, CHCl3);
HRMS for (M+ + H): calcd m/z 611.2281, found: 611.2260.
3′R,4′R-Di-(cyclohexanecarbonyloxy)-2′,2′-dimethyl-2-ethyl-dihydropyrano[2,3-
f]chromone (23)—20 % yield (starting from 25 mg of 4); white solid; mp = 72-74
°C; 1NMR δ 8.08 (1H, d, J = 9.0 Hz, H-5), 6.88 (1H, d, J = 9.0 Hz, H-6), 6.61 (1H, d, J =
4.5 Hz, H-4′), 6.12 (1H, s, H-3), 5.27 (1H, d, J = 4.5 Hz, H-3′), 2.56 (2H, q, J = 7.5 Hz,
CH2CH3-2), 2.35 (2H, m, cyclohexanecarbonyl-3′,4′), 2.80 (12H, m,
cyclohexanecarbonyl-3′,4′), 1.49, 1.42 (each 3H, s, CH3-2′), 1.35 (8H, m,
cyclohexanecarbonyl-3′,4′), 1.23 (3H, t, J = 7.5 Hz, CH2CH3-2); [α]D −15.4 ° (c = 0.005,
CHCl3); HRMS for (M+ + H): calcd m/z 511.2696, found: 511.2713.
Synthesis of 3′R,4′R-Dibenzyloxy-2′,2′-dimethyl-2-ethyl-dihydropyrano[2,3-
f]chromone (22)—NaH (20.4 mg, 0.51 mmoL) was suspended in dry DMF. To this
suspension were added at 0 °C a solution of compound 4 (50 mg, 0.17 mmoL) in dry DMF
(0.5 mL), and benzyl bromide (0.05 mL, 0.43 mmoL), under the protection of N2. After 1 h,
the mixture was poured into 5% aqueous NaHCO3 solution and extracted with Et2O for
three times. The organic layers were combined and dried over Na2SO4. The crude product
was purified by preparative TLC with hexane:EtOAc = 1:1 to afford 21 (16.2 mg, white
solid). 57.3 % yield; mp = 77-79 °C; 1NMR δ 8.00 (1H, d, J = 8.7 Hz, H-5), 7.41, 7.28 (each
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5H, m, benzyl-3′,4′), 6.81(1H, d, J = 8.7 Hz, H-6), 6.13 (1H, s, H-3), 5.10, 4.95, 4.85, 4.75
(each 1H, d, J = 11.4 Hz, benzyl-CH2-3′,4′)5.09 (1H, d, J = 4.2 Hz, H-4′), 3.75 (1H, d, J =
4.2 Hz, H-3′), 2.60 (2H, q, J = 7.5 Hz, CH2CH3-2), 1.57, 1.50 (each 3H, s, CH3-2′), 1.28
(3H, t, J = 7.5 Hz, CH2CH3-2); [α]D −40.9 ° (c = 0.01, CHCl3); HRMS for (M+ + H): calcd
m/z 471.2171, found: 471.2155.
Synthesis of compounds 24-28—Sodium hydride (5 equiv) was added to a solution of
compound 4 in dry THF at ice-bath condition and diverse carbamyl chlorides (3 equiv) were
added. The reaction mixture was stirred at rt and monitored by TLC. At completion, the
reaction mixture was poured carefully onto EtOAc and saturated aqueous NaHCO3. The
organic layer was washed with water for three times, dried over anhydrous MgSO4, and
evaporated under reduced pressure. The crude product was purifed by prepare TLC.
3′R,4′R-Di-(dimethylcarbamoyloxy)-2′,2′-dimethyl-2-ethyl -dihydropyrano[2,3-
f]chromone (24)—30% yield (starting from 100 mg of 4); clear oil; 1NMR δ 8.07 (1H, d,
J = 8.8 Hz, H-5), 6.88 (1H, d, J = 8.8 Hz, H-6), 6.52 (1H, d, J = 4.8 Hz, H-4′), 6.11 (1H, s,
H-3), 5.22 (1H, d, J = 4.8 Hz, H-3′), 2.97, 2.85 (each 6H, m, dimethylcarbamoyl-CH2-3′,4′),
2.55 (2H, q, J = 7.2 Hz, CH2CH3-2), 1.49, 1.46 (each 3H, s, CH3-2′), 1.24 (3H, t, J = 7.2 Hz,
CH2CH3-2); [α]D −28.6 ° (c = 0.01, CHCl3); HRMS for (M+ + H): calcd m/z 433.1957,
found: 433.1951.
3′R,4′R-Di-(diethylcarbamoyloxy)-2′,2′-dimethyl-2-ethyl -dihydropyrano[2,3-
f]chromone (25)—25% yield (starting from 25 mg of 4); white solid; mp = 125-126
°C; 1NMR δ 8.07 (1H, d, J = 8.8 Hz, H-5), 6.88 (1H, d, J = 8.8 Hz, H-6), 6.59 (1H, d, J =
4.8 Hz, H-4′), 6.11 (1H, s, H-3), 5.25 (1H, d, J = 4.8 Hz, H-3′), 3.35, 3.35, 3.18, 3.18 (each
2H, q, J = 6.8 Hz, diethylcarbamoyl-CH2-3′,4′), 2.55 (2H, q, J = 7.6 Hz, CH2CH3-2), 1.49,
1.47 (each 3H, s, CH3-2′), 1.23 (3H, t, J = 7.6 Hz, CH2CH3-2), 1.16 (6H, t, J = 6.8 Hz,
diethylcarbamoyl-CH3-4′), 1.09, 0.98 (each 3H, t, J = 6.8 Hz, diethylcarbamoyl-CH3-3′);
[α]D −30.0 ° (c = 0.001, CHCl3); HRMS for (M+ + H): calcd m/z 489.2601, found:
489.2594.
3′R,4′R-Di-(dibutylcarbamoyloxy)-2′,2′-dimethyl-2-ethyl -dihydropyrano[2,3-
f]chromone (26)—30% yield (starting from 50 mg of 4); clear oil; 1NMR δ 8.06 (1H, d, J
= 8.8 Hz, H-5), 6.86 (1H, d, J = 8.8 Hz, H-6), 6.58 (1H, d, J = 4.8 Hz, H-4′), 6.11 (1H, s,
H-3), 5.23 (1H, d, J = 4.8 Hz, H-3′), 3.25 (8H, m, dibutylcarbamoyl-3′,4′), 2.56 (2H, q, J =
7.6 Hz, CH2CH3-2), 1.57 (6H, m, dibutylcarbamoyl-CH2), 1.47, 1.46 (each 3H, s, CH3-2′),
1.33 (8H, m, dibutylcarbamoyl-CH2), 1.25 (3H, t, J = 7.6 Hz, CH2CH3-2), 1.08 (2H, q, J =
7.2 Hz, dibutylcarbamoyl-CH2-3′), 0.95, 0.94 (each 3H, t, J = 7.6 Hz, dibutylcarbamoyl-
CH3-4′), 0.86, 0.72 (each 3H, t, J = 7.2 Hz, dibutylcarbamoyl-CH3-3′); [α]D −13.5 ° (c =
0.012, CHCl3); HRMS for (M+ + H): calcd m/z 601.3853, found: 601.3833.
3′R,4′R-Di-(pyrrolidine-1-carbonyloxy)-2′,2′-dimethyl-2-ethyl-
dihydropyrano[2,3-f] chromone (27)—35% yield (starting from 25 mg of 4); white
powder; mp = 104-106 °C; 1NMR δ 8.05 (1H, d, J = 8.8 Hz, H-5), 6.87 (1H, d, J = 8.8 Hz,
H-6), 6.54 (1H, d, J = 4.8 Hz, H-4′), 6.11 (1H, s, H-3), 5.23 (1H, d, J = 4.8 Hz, H-3′), 3.48,
3.26 (each 4H, m, pyrrolidine-N(CH2)2(CH2)2-3′,4′), 2.55 (2H, q, J = 7.6 Hz, CH2CH3-2),
1.86 (8H, m, pyrrolidine-N(CH2)2(CH2)2-3′,4′), 1.50, 1.47 (each 3H, s, CH3-2′), 1.21 (3H, t,
J = 7.6 Hz, CH2CH3-2); [α]D −23.8 ° (c = 0.011, CHCl3); HRMS for (M+ + H): calcd m/z
485.2288, found: 485.2277.
3′R,4′R-Di-(piperidine-1-carbonyloxy)-2′,2′-dimethyl-2-ethyl-dihydropyrano[2,3-
f]chromone (28)—32% yield (starting from 25 mg of 4); white solid; mp = 107-109
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°C; 1NMR δ 8.06 (1H, d, J = 8.8 Hz, H-5), 6.87 (1H, d, J = 8.8 Hz, H-6), 6.56 (1H, d, J =
4.8 Hz, H-4′), 6.11 (1H, s, H-3), 5.24 (1H, d, J = 4.8 Hz, H-3′), 3.77 (8H, m, piperidine-
N(CH2)2(CH2)2CH2-3′,4′), 2.57 (2H, q, J = 7.6 Hz, CH2CH3-2), 1.58 (12H, m, piperidine-
N(CH2)2(CH2)2CH2-3′,4′), 1.47, 1.46 (each 3H, s, CH3-2′), 1.26 (3H, t, J = 7.6 Hz,
CH2CH3-2); [α]D −28.2 ° (c = 0.0017, CHCl3); HRMS for (M+ + H): calcd m/z 513.2601,
found: 513.2620.
Chemosensitization (MDR Modulation) Assay—Three thousand drug-resistant cells,
KB-Vin cells (MDR-1) selected using VCR 16 were treated for two or three days with test
agent in the presence or absence of VCR. The end-point is cellular protein measured using
the sulforhodamine B (SRB) method developed at NIH-NCI for in vitro anticancer drug
screening.17 The degree of chemoreversal was determined by fixing the concentration of test
agent and measuring the alteration in dose-response of cells to VCR toxicity. Verapamil was
used as chemosensitizer control. Data from replicate experiments were plotted, and the
apparent GI50 value was determined using statistical software (GraphPad Prizm, CA).
Calcein-AM Loading Assay—KB-Vin (MDR) cells (10,000 per well) were seeded into
96-well plates with medium containing 5% FBS and incubated for one day for adhesion and
equilibration. Treatment involved supplementing cultures with distinct concentrations of test
compounds for 30 min at 37 °C. After removing medium, fresh medium with both 1 μM
calcein-AM (Alexis Biochemicals) and test compounds as needed was then replaced.
Following incubation for 30 min at 37 °C, medium was removed and wells were washed
gently and quickly with cold PBS buffer in low ambient light conditions. Cells were lysed
using 20 mM Tris-HCl buffer and fluorescence was measured using a BioTek TLx800
ELISA reader set to Ex. 494 nm and Em. 517 nm. Composite data obtained from two or
more independent experiments were analyzed using Prizm™ (Graphpad Software, San
Diego, CA).15
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Structures of (+/−) Praeruption A, DCK, MMDCK, DMDCK and DSP
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Synthesis of 3′,4′-dibenzoyl-pyranodihydrochromone derivatives (5 - 28). Reagents and
Condition: (i) diverse benzoyl chlorides, DMAP, anhydrous CH2Cl2, rt ;(ii) phenylacetyl
chlorides or 3-phenylpropanoyl chloride, DMAP, anhydrous CH2Cl2, rt; (iii) trans-
cinnamoyl chlorides, DMAP, CH2Cl2, rt; (iv) cyclohexanecarbonyl chloride, DMAP,
anhydrous CH2Cl2, rt; (v) benzyl bromide, NaH/DMF, N2, 0°C; (vi) diverse
dialkylcarbamyl chlorides or cyclocarbamyl chlorides, NaH, rt.
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